

Selehold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg

Authorised

- Selamectin

Product identification

Medicine name:

Selehold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg

Selehold, 15 mg täpilahus kassidele ja koertele kehamassiga $\leq 2,5$ kg

Active substance:

Selamectin

Target species:

Dog

Cat

Route of administration:

Spot-on use

Product details

Active substance and strength:

Selamectin

15.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AA05

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Estonia

Available in:

Estonia

Package description:

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution. Cardboard box containing 1 pipette.

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution. Cardboard box containing 3 pipettes.

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution. Cardboard box containing 6 pipettes.

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution. Cardboard box containing 15 pipettes.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

5/11/2018

Manufacturing sites for batch release:

TAD Pharma GmbH

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

State Agency Of Medicines

Authorisation number:

2121

Date of authorisation status change:

5/11/2018

Reference member state:

Ireland

Procedure number:

IE/V/0394/001

Concerned member states:

Belgium Bulgaria Croatia Czechia Estonia France Germany Greece Hungary
Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia
Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 3/05/2024

Download